Stock AnalizAxsome Therapeutics, Inc. AXSM
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Axsome Therapeutics, Inc. (AXSM) is a healthcare company listed in the US with a market value of about $7.5B. In the twelve months to September 30, 2026 it had revenue of $865M and net income of -$157M, a net margin of -18.2%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -94%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $865M | $638M | $386M | $271M | $50M | — | — | — | — | — | — |
| Net income | -$157M | -$183M | -$287M | -$239M | -$187M | -$130M | -$103M | -$68M | -$31M | -$29M | -$27M |
| Free cash flow | -$83M | -$94M | -$129M | -$146M | -$117M | -$109M | -$79M | -$46M | -$30M | -$26M | -$21M |
| EPS (diluted) | $-3.05 | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 | $-2.77 | $-2.01 | $-1.15 | $-1.27 | $-1.42 |
| Net margin | -18.2% | -28.7% | -74.5% | -88.4% | -374.0% | — | — | — | — | — | — |
| ROIC | — | -55.5% | -90.2% | -48.3% | -87.7% | -188.2% | -47.3% | -26.7% | -330.6% | -80.5% | -69.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 21 analysts is $265.86, 88% above the current price; targets range from $220.00 to $315.00; the consensus rating is “Strong buy”; expected EPS is $-2.53 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Axsome Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Axsome Therapeutics pay a dividend?
Not currently.
Is Axsome Therapeutics a good stock to buy?
We do not give buy or sell advice. Axsome Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.